Mohammad Rudiansyah
Divisi Ginjal Dan Hipertensi, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Lambung Mangkurat / RSUD Ulin Banjarmasin, Indonesia.

Published : 22 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 22 Documents
Search

Prognostic Nutritional Index (PNI) at Admission Predicts In-Hospital Mortality of COVID-19-Infected Patients Haryati, Haryati; Isa, Mohamad; Rudiansyah, Mohammad; Juhairina, Juhairina; Nor, Muhamad; Arganita, Fidya Rahmadhany
Majalah Kedokteran Bandung Vol 57, No 2 (2025)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15395/mkb.v57.3930

Abstract

Corona Virus Disease-2019 (COVID-19) was declared a pandemic in March 2020 and caused considerable deaths in all parts of the world. Mortality is influenced by the immune system status and increased vulnerability to infection, both related to nutritional status. The Prognostic Nutritional Index (PNI), calculated using lymphocyte count and albumin levels, may have the ability to more accurately characterize the nutritional and inflammatory conditions of COVID-19 patients. This retrospective study analyzed 967 COVID-19 patients at Ulin Hospital Banjarmasin, Indonesia, by examining demographic data, laboratory results, and PNI in relation to survival outcomes. The study revealed that factors such as age, sex, comorbidities (including hypertension, diabetes mellitus/DM, obesity, etc.), number of comorbidities, and disease severity correlated with mortality. Leucocyte count, lymphocyte count, albumin levels, and PNI all showed significant correlations with survival (p<0.001), suggesting that these factors may serve as useful prognostic indicators for COVID-19 patient’s survival. The PNI was associated with an increased risk of mortality, with a univariate odds ratio (OR) of 0.923. Receiver operating characteristic (ROC) analysis demonstrated that a PNI cut-off value of p<41.9 had a sensitivity of 44.9% and a specificity of 82.4%, with an area under the curve (AUC) of 0.666 (p<0.001). Hence, PNI at admission, which reflects patients' immune system and nutritional status upon hospital admission, can be used as a simple, cost-effective, and reliable predictor of mortality in COVID-19 patients.
Comparison of stingless bee honey and silver sulfadiazine on diabetic wound healing in rat models Fajari, Nanang Miftah; Pranoto, Agung; Perdanakusuma, David Sontani; Prenggono, Muhammad Darwin; Rudiansyah, Mohammad; Nur'amin, Hendra Wana; Syarifa, Yulia; Hasrianti, Nuvita; Saputri, Imelda Nita; Afrianto, Muhammad Irawan; Husna, Annisa Halida
Medical Journal of Indonesia Vol. 34 No. 3 (2025): September
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13181/mji.oa.257974

Abstract

BACKGROUND Diabetic foot ulcers (DFUs) are a major health concern in Indonesia. Adjuvant therapies may improve healing by avoiding secondary infections, promoting angiogenesis, and supporting oxygen circulation. This aimed to evaluate the effect of stingless bee honey (SBH) from Heterotrigona itama on diabetic wound size in rats (Rattus norvegicus), compared to silver sulfadiazine (SSD). METHODS An experimental study was conducted on 13 diabetic wounds in streptozotocin-induced diabetic rats treated with three types of therapies: SSD (n = 5), pure SBH (n = 5), and SBH with 20% water content (n = 3). The study initially involved 21 rats, but eight died during the diabetes modeling and wound observation phases, presumably due to hyperglycemia. Baseline characteristics did not differ significantly across the groups. RESULTS SBH with 20% water content and pure SBH reduced wound size by 95.1% and 92.1%, outperforming SSD (77.4%), with all therapies showing statistically significant improvement (p<0.05). However, the differences between groups were not statistically significant (p = 0.162). CONCLUSIONS Topically applied SBH is a potential natural therapeutic agent for diabetic wounds, in addition to standard treatment such as SSD.